History-aware, append-only, query-safe. Nexum connects sponsors, trials, sites, and outcomes into a unified relationship spine—built to plug into research pipelines with institutional reliability.
Direct PostgreSQL access, REST, and GraphQL endpoints. Use your existing tools—no proprietary SDK required. Every query is reproducible, every result is versioned.
Unlike vendor-locked platforms, Nexum gives you direct database access with a stable schema, full version history, and reproducible queries.
Every update becomes an immutable event. Full audit trail, point-in-time queries, zero data loss.
Connect sponsors, sites, investigators, and outcomes. See the complete clinical execution network.
No breaking schema changes. Save queries, add parameters, cache results. Built for reproducibility.
Sub-2-minute latency from public registries. WebSocket updates for live dashboards.
PostgreSQL wire protocol, REST, and GraphQL. Use your existing tools and workflows.
99.9% uptime guarantee. Dedicated support. On-premises deployment options available.
Join research teams using Nexum to power reproducible, query-safe clinical data pipelines.
Nexum is built as infrastructure: append-only events, deterministic diffs, and provenance you can audit. No opinions in the core—just query-safe truth with memory.
From oncology researchers to hedge fund analysts—see how teams use Nexum to monitor trials, track drift, and identify market signals.
Track 2,847 active oncology trials across Phase II–III. Monitor enrollment velocity, completion drift, and sponsor performance. Updated daily from ClinicalTrials.gov snapshots.
| Trial ID | Sponsor | Indication | Phase | Original Date | Current Est. | Drift | Risk |
|---|---|---|---|---|---|---|---|
| NCT05847392 | BioNova | NSCLC | Phase III | Dec 2025 | Aug 2026 | +245d | HIGH |
| NCT04123987 | Novartis | Melanoma | Phase II | Mar 2026 | Sep 2026 | +189d | HIGH |
| NCT05234567 | Roche | Breast Cancer | Phase III | Jun 2026 | Nov 2026 | +156d | MEDIUM |
Comparative performance metrics across top sponsors. Track portfolio health, execution consistency, and competitive positioning in real-time.
| Rank | Sponsor | Active Trials | Avg Drift | On-Time % | Performance |
|---|---|---|---|---|---|
| 1 | AstraZeneca | 143 | -12d | 87% | EXCELLENT |
| 2 | Roche | 234 | +18d | 78% | GOOD |
| 3 | Merck | 147 | +34d | 72% | GOOD |
| 4 | Novartis | 198 | +87d | 58% | FAIR |
Deep-dive into completion date drift patterns. Track velocity, forecast future delays, and identify systemic execution issues before they compound.
| Trial ID | Sponsor | Current Drift | Velocity | 30d Forecast | Alert Level |
|---|---|---|---|---|---|
| NCT05847392 | BioNova | +245d | +12d/wk | +293d | CRITICAL |
| NCT04987234 | MedTech Inc | +178d | +9d/wk | +214d | CRITICAL |
| NCT05123456 | Novartis | +134d | +7d/wk | +162d | HIGH |
Actionable trial intelligence for hedge funds and biotech investors. Track material events, catalyst timelines, and competitive positioning. Detect alpha-generating signals 5-10 days before market pricing.
| Date | Event Type | Sponsor (Ticker) | Trial | Signal | Impact |
|---|---|---|---|---|---|
| Feb 4 | Major Delay | BioNova (BNVA) | NCT05847392 | 🔻 Bearish | HIGH |
| Feb 3 | Early Completion | Novartis (NVS) | NCT04123456 | 🔺 Bullish | MEDIUM |
| Feb 2 | Enrollment Complete | Merck (MRK) | NCT05234789 | 🔺 Bullish | MEDIUM |
| Feb 1 | Trial Terminated | SmallCap Bio (SMCP) | NCT04987234 | 🔻 Bearish | HIGH |
| Est. Date | Catalyst | Sponsor | Trial | Indication | Confidence |
|---|---|---|---|---|---|
| Feb 15 ±7d | Primary Completion | Roche | NCT04556789 | Melanoma Phase III | High (92%) |
| Feb 22 ±10d | Enrollment Target | AstraZeneca | NCT05123987 | NSCLC Phase II | Medium (74%) |
| Mar 5 ±14d | Study Completion | BMS | NCT04789234 | CRC Phase III | Medium (68%) |
From trial monitoring to market intelligence—Nexum provides the infrastructure for clinical data insights.
Nexum is an append-only ingestion ledger for clinical trials—turning public registry updates into queryable clinical events with full history and provenance.
Most tracked conditions
Trials by phase
Daily trial ingestion
Loading recent trials...
For now, explore our Live Data preview. When you're ready, we'll add a waitlist and API keys for full platform access.
Search top-performing research sites by name, location, or specialty